Evidence map›Paper›PMID 25246739›Full record

Trial reportJournal of Korean medical science2014

Benefits of a continuous ambulatory peritoneal dialysis (CAPD) technique with one icodextrin-containing and two biocompatible glucose-containing dialysates for preservation of residual renal function and biocompatibility in incident CAPD patients.

Hye Eun Yoon, Yoon Kyung Chang, Seok Joon Shin, Bum Soon Choi, Byung Soo Kim, Cheol Whee Park, Ho Cheol Song, Sun Ae Yoon, Dong Chan Jin, Yong-Soo Kim

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of Korean medical science, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Biocompatible dialysis fluids for peritoneal dialysis.The Cochrane database of systematic reviews · 2018
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Hye Eun YoonDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID 0000-0002-6347-7282
Yoon Kyung ChangDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID 0000-0003-4193-2034
Seok Joon ShinDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID 0000-0001-7642-2849
Bum Soon ChoiDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID 0000-0002-1412-9951
Byung Soo KimDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID 0000-0001-5034-9014
Cheol Whee ParkDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID 0000-0002-9912-5393
Ho Cheol SongDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID 0000-0002-9849-8091
Sun Ae YoonDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID 0000-0003-1175-8098
Dong Chan JinDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID 0000-0002-6637-8263
Yong-Soo KimDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID 0000-0003-2152-1289
Catholic University of Korea · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In a prospective randomized controlled study, the efficacy and safety of a continuous ambulatory peritoneal dialysis (CAPD) technique has been evaluated using one icodextrin-containing and two glucose-containing dialysates a day. Eighty incident CAPD patients were randomized to two groups; GLU group continuously using four glucose-containing dialysates (n=39) and ICO group using one icodextrin-containing and two glucose-containing dialysates (n=41). Variables related to residual renal function (RRF), metabolic and fluid control, dialysis adequacy, and dialysate effluent cancer antigen 125 (CA125) and interleukin 6 (IL-6) levels were measured. The GLU group showed a significant decrease in mean renal urea and creatinine clearance (-Δ1.2 ± 2.9 mL/min/1.73 m(2), P=0.027) and urine volume (-Δ363.6 ± 543.0 mL/day, P=0.001) during 12 months, but the ICO group did not (-Δ0.5 ± 2.7 mL/min/1.73 m(2), P=0.266; -Δ108.6 ± 543.3 mL/day, P=0.246). Peritoneal glucose absorption and dialysate calorie load were significantly lower in the ICO group than the GLU group. The dialysate CA125 and IL-6 levels were significantly higher in the ICO group than the GLU group. Dialysis adequacy, β2-microglobulin clearance and blood pressure did not differ between the two groups. The CAPD technique using one icodextrin-containing and two glucose-containing dialysates tends to better preserve RRF and is more biocompatible, with similar dialysis adequacy compared to that using four glucose-containing dialysates in incident CAPD patients. [Clincal Trial Registry, ISRCTN23727549].

Indexed as

AdultAgedCA-125 AntigenCreatinineDialysis SolutionsFemaleGlomerular Filtration RateGlucansGlucoseHumansIcodextrinInterleukin-6KidneyKidney Failure, ChronicMaleMembrane ProteinsCA-125 AntigenCreatinineDialysis SolutionsGlucansGlucoseIcodextrinInterleukin-6Membrane ProteinsMUC16 protein, humanUreaBiocompatibilityIcodextrin, Randomized Controlled TrialPeritoneal Dialysis, Continuous AmbulatoryResidual Renal Function

Identifiers

PMID25246739
PMCPMC4168174
OpenAlexW2165398002

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.